# Trill Impact

> Trill Impact is a VC fund in Stockholm backing Health Care and Biotechnology. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 18
- Last investment: Mar 2026
- Lead investor: 39%
- Fund size: $1.1B
- Last fund: Sep 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/trill-impact/
- Website: https://www.trillimpact.com/
- Facebook: https://www.facebook.com/trillimpact

Trill Impact is a private equity firm targeting mid-sized companies in Northern Europe with the potential to accelerate value creation while contributing to the Sustainable Development Goals. Trill Impact aims for global leadership in Impact Private Equity through its active and proprietary impact investing and ownership approach.

## Contacts

5 contacts available for Trill Impact. Shizune tracks 3 team members at Trill Impact. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/trill-impact?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 22% |
| Biotechnology | 3 | 17% |
| Farming | 2 | 11% |
| Medical | 2 | 11% |
| Software | 2 | 11% |

43 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 6 | 33% |
| Private Equity | 4 | 22% |
| Series B | 3 | 17% |
| Funding Round | 2 | 11% |
| Series A | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 3 | 17% |
| Denmark | 2 | 11% |
| Germany | 2 | 11% |
| United States | 2 | 11% |
| United Kingdom | 2 | 11% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jan Stahlberg | Founder and Managing Partner | 4 | — |
| Alexander Domin | Partner and Head of Ventures | 4 | https://shizune.co/investors/profile/alex-domin |
| Viktor Andersson | Head of Microfinance | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| May Health | AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is donetransvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF. | $11.6M | Venture - Series Unknown | Mar 10, 2026 |  |
| Rail-Flow | Rail-Flow provides purchase and tender management, rail offer management, intermodal transportation management, intermodal capacity brokers, transport management, and automatic order entry. Their customers contact them through phone, email, and online applications. | $14.6M | Series A | Dec 03, 2025 |  |
| Soil Capital Belgium | Soil Capital supports farmers with transitioning from industrial to regenerative organic farming. | $16.6M | Series B | Sep 03, 2024 |  |
| May Health | AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is donetransvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF. | $24.8M | Series B | May 13, 2024 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M |  | Oct 11, 2023 |  |
| Open Cosmos | Open Cosmos is a space technology company that designs, builds, and operates satellites to simplify access to space. The company also delivers end-to-end telecommunications, Earth Observation (EO), navigation, and scientific missions. It designs, builds, launches and operates advanced satellites through its OpenOrbit offering, that enablesorganizations to access and share data via its mutualized OpenConstellation infrastructure and offers AI-powered data analysis from a growing range of satellite sources and analytic partners through its DataCosmos platform. | $50M | Series B | Sep 11, 2023 |  |
| tado° | Tado° develops a heating app for private homes and small businesses. It adjusts to the residents' behavior in real-time and also takes current weather forecasts and building characteristics into account. Tado° is committed to changing how heating and cooling systems function in structures, minimizing energy waste, and lowering carbonemissions. The company regulates indoor temperatures using automation and various control methods. The company's application allows users to modify settings, track usage, and access reports. Integration with smart home systems enables temperature adjustments via voice commands. Features such as geofencing change settings based on occupancy, while weather adaptation adjusts heating or cooling according to forecasts. Intelligent scheduling helps users create personalized temperature plans, and automation capabilities handle climate control without requiring manual intervention. | $46.8M | Venture - Series Unknown | Jan 26, 2023 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M | Series C | Dec 15, 2022 |  |
| Cinclus Pharma | Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $24.1M | Venture - Series Unknown | May 20, 2022 |  |
| Delivery Associates | Delivery Associates is a management advisory services company. They were intended for governments and social impact organisations. They devise systems and software and provide training for implementing policies, thereby enabling clients to make progress on their ideas and fulfil their ambitions. |  | Private Equity | Jan 01, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 2 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 2 deals together
- [LF Investment](https://shizune.co/investors/profile/lf-investment) — VC Fund, 2 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together
- [Pureos Bioventures](https://shizune.co/investors/profile/pureos-bioventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Trill Impact invest in?

Trill Impact invests primarily in Health Care, Biotechnology and Farming startups, most often at Venture - Series Unknown and Private Equity stage. Most of the 18 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Trill Impact?

Public channels for Trill Impact include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Trill Impact?

The team at Trill Impact includes Jan Stahlberg (Founder and Managing Partner), Alexander Domin (Partner and Head of Ventures) and Viktor Andersson (Head of Microfinance). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co